Merck announces favorable English Court ruling on name use
Court says MSD breached an agreement with Merck by using "Merck" alone either as a trade mark or a name in the UK.
Merck has secured a favorable ruling in the English High Court following almost 3 years of litigation with US-based Merck Sharp & Dohme Corp. (MSD) regarding the use of the term "Merck".
In its judgement the English High Court stated that MSD had breached an agreement with the company by using "Merck" alone in the UK either as a trade mark or a name, online or offline. Merck and MSD had entered the agreement in 1955 and amended it in 1970. According to this agreement, Merck is entitled to use the name everywhere in the world, except the US and Canada.
"Our objective has been to protect the status quo established in the existing agreement,” said Friederike Rotsch, General Counsel at Merck. “Therefore, we are pleased that the English court has upheld our argument that MSD’s use of our name and brand 'MERCK' in our territories is beyond the limits agreed with MSD."
Merck relaunched its brand identity last year to reflect the transformation into a global science and technology company with three strong businesses in Healthcare Life Science and Performance Material and create a distinct identity vis-à-vis its patients, customers and investors across various industries and geographies.
The judge said Merck was entitled to an order to prevent MSD from describing itself in any printed or digital material addressed to the UK as "'Merck" alone, and restraining MSD's use of the trade mark "MERCK" alone. The judge also held that MSD’s use of “Merck” as part of branding on its global websites were directed to the UK and infringed Merck’s trade mark rights in the UK.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.